Reviewing past treatment and survival in people with high-grade osteosarcoma
Looks back at records of people treated for high-grade osteosarcoma in Korea.
Plain-language title generated from the registry record
Registry title: Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
Key facts
- Where
- Goyang-si and Seoul, South KoreaSee the 4 sites
Where in South Korea
- National Cancer CenterGoyang-si, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaNot yet recruiting
- Korea Cancer Center HospitalSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- MedPacto, Inc.
- Trial code
- NCT07878364
- Record updated
- 16 October 2026
- Original description
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea. The study describes treatment patterns and survival outcomes (event-free survival [EFS], progression-free survival [PFS], and overall survival [OS]) in patients who completed or discontinued first-line treatment for high-grade osteosarcoma, irrespective of complete remission status. The primary objective is to retrospectively estimate the 12-month EFS rate, calculated from the date of diagnosis, in the full cohort of high-grade osteosarcoma patients. Key secondary objectives evaluate EFS and OS from the date of confirmed complete remission/no evidence of disease (CR/NED) in the subset of clinically high-risk patients who achieve CR/NED, in order to establish a historical reference data supporting the design and interpretation of a future prospective clinical trial of vactosertib as maintenance therapy.Read full original descriptionShow less
A Multicenter Medical-Record-Based Retrospective Study of Treatment Patterns and Survival Outcomes in Patients With High-Grade Osteosarcoma
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea. The study describes treatment patterns and survival outcomes (event-free survival [EFS], progression-free survival [PFS], and overall survival [OS]) in patients who completed or discontinued first-line treatment for high-grade osteosarcoma, irrespective of complete remission status. The primary objective is to retrospectively estimate the 12-month EFS rate, calculated from the date of diagnosis, in the full cohort of high-grade osteosarcoma patients. Key secondary objectives evaluate EFS and OS from the date of confirmed complete remission/no evidence of disease (CR/NED) in the subset of clinically high-risk patients who achieve CR/NED, in order to establish a historical reference data supporting the design and interpretation of a future prospective clinical trial of vactosertib as maintenance therapy.
Inclusion: Pathologically diagnosed high-grade osteosarcoma; age ≥12 years; First-line treatment for high-grade osteosarcoma completed or ended at the study institution on or before 2021-06-30; Core data required for survival endpoint assessment (EFS, PFS, OS) are available, with at least one of the following satisfied: (a) at least 12 months of follow-up from the date of diagnosis; or (b) an event (relapse, metastasis, disease progression, or death from any cause) confirmed within 12 months of diagnosis.
Exclusion: History of a malignancy other than primary osteosarcoma, unless clinically insignificant and fully treated prior to osteosarcoma diagnosis with no investigator-judged impact on osteosarcoma treatment course or survival analysis; Primary tumor of soft-tissue origin rather than bone, confirmed pathologically; Core data required for survival analysis cannot be verified; Transferred to another institution with no available follow-up information, where neither event occurrence, last follow-up date, nor survival status can be determined from pre-transfer records; Investigator-judged data errors or inconsistencies.